Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025

Company Overview - Drugs Made In America Acquisition II Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands, aimed at effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses [4] - The company has not yet selected a specific business combination target and has not engaged in substantive discussions with any potential targets [4] - The company intends to focus its search for business combinations in the pharmaceutical industry, aiming to mitigate risks in the U.S. medical supply chain by investing in companies that reduce reliance on concentrated geographic production of pharmaceuticals [4] Trading Information - Starting December 3, 2025, holders of units from the initial public offering (IPO) completed on September 26, 2025, can separately trade the ordinary shares and rights on the Nasdaq Global Market [1] - The ordinary shares and rights will trade under the symbols "DMII" and "DMIIR," respectively, while units that are not separated will continue to trade under the symbol "DMIIU" [2] - The units were initially offered in an underwritten offering, with Cantor Fitzgerald & Co. acting as the sole book-running manager [3]